GlassScriptPhysician profile
Mary M Kim
NPI 1902880123
$9,302.22
in general payments reported to CMS, 2019-2025
43 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,752 · 2020: $1,774 · 2021: $1,094 · 2022: $1,019 · 2023: $1,197 · 2024: $1,292 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,601 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,600.98 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,722.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,261.14 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $997.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $995.74 | 2019-2025 | |
| Lilly USA, LLC | $887.98 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $600.32 | 2019-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $371.09 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $309.12 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $232.15 | 2019-2020 | |
| Abbott Laboratories | $213.89 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $152.75 | 2019-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $125.24 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $125.09 | 2022-2025 | Quviviq, Quviviq |
| Janssen Pharmaceuticals, INC | $124.11 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $104.86 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.